Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 12 min ago
Peer-reviewedLicence not statedJAMA

Single Intranasal Administration of the Psychedelic Mebufotenin for Treatment-Resistant Depression

3 more authors
12 affiliations
  1. 1Kadima Neuropsychiatry Institute, La Jolla, California
  2. 2Department of Psychological Medicine, Institute of Psychiatry, Psychology, and Neuroscience, King’s College London, London, United Kingdom
  3. 3AtaiBeckley, Oxford, United Kingdom
  4. 4Department of Psychiatry, Medical University of Gdańsk, Gdańsk, Poland
  5. 5Department of Molecular Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
  6. 6German Center for Mental Health (DZPG) Partner Site, Mannheim-Heidelberg-Ulm, Germany
  7. 7Parc Sanitari Sant Joan de Deu, Barcelona, Spain
  8. 8Department of Psychiatry, Monash University, Melbourne, Victoria, Australia
  9. 9AIM Trials, Plano, Texas
  10. 10Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Psychiatry and Neurosciences, Campus Charité Mitte, Berlin, Germany
  11. 11German Center for Mental Health (DZPG) Partner Site, Berlin-Potsdam, Germany
  12. 12Beckley Psytech Ltd, Oxford, United Kingdom

Related

  1. Quality of Life in Patients with Treatment-Resistant Depression Treated with Intranasal Esketamine as Add-On Therapy to an SSRI-A Prospective, Comparative Study in Real-World Clinical Practice.
    Daniel Szawarnoga, Joanna Fojcik, Michał Górski +1
    Pharmaceuticals (Basel, Switzerland)Peer-reviewedCC BYFull textPharmacology & toxicologyEurope PMC
  2. Development of a Multivalent Macrocyclic Peptide that Protects Against SARS-CoV-2 Infection Following Intranasal Administration
    Antonius J.P. Hopstaken, Aneta Zegar, Oliver J. Debski-Antoniak +13
    ChemRxivPreprintCC BYFull textInfectious diseaseChemRxiv
  3. Effects of multiple low-dose intranasal dexmedetomidine administration on postoperative pulmonary complications in elderly patients undergoing thoracoscopic radical resection of lung cancer: a single-center randomized controlled trial
    Bing Li, Yao Liu, Xinmin Liu +5
    Frontiers in pharmacologyPeer-reviewedCC BYFull textSurgery & anaesthesiaEurope PMCCrossref
  4. Co-administration of intranasal parainfluenza virus vaccines expressing antigenically distinct SARS-CoV-2 S antigens elicits broad and durable immunity in hamsters
    Hong-Su Park, Yumiko Matsuoka, Celia Santos +9
    Journal of VirologyPeer-reviewedCC BY 4.0Full textInfectious diseasePMC
  5. Vitamin B1 administration attenuates anxiety and depression-like behaviors induced by nicotine abstinence in chronically stressed rats
    Alireza Najafzadeh, Samaneh Kakhki, Seyed Amirsadra Khatibi +3
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textNeurologyCrossref
BibTeX
@article{feifel2026single,
  title = {{Single Intranasal Administration of the Psychedelic Mebufotenin for Treatment-Resistant Depression}},
  author = {David Feifel and Mathieu Seynaeve and Wiesław Jerzy Cubała and Fiona Dunbar and Gerhard Gründer and Rosa María Dueñas Herrero and Chandni Hindocha and Paul Liknaitzky and Sean M. McGuigan and Sejal Mehta and Mimi Pierce and Dimitris Repantis and Claire Roberts and Frank Wiegand and Robert Conley},
  journal = {JAMA},
  year = {2026},
  month = oct,
  doi = {10.1001/jama.2026.18380},
  url = {https://doi.org/10.1001/jama.2026.18380},
}
RIS
TY  - JOUR
TI  - Single Intranasal Administration of the Psychedelic Mebufotenin for Treatment-Resistant Depression
AU  - David Feifel
AU  - Mathieu Seynaeve
AU  - Wiesław Jerzy Cubała
AU  - Fiona Dunbar
AU  - Gerhard Gründer
AU  - Rosa María Dueñas Herrero
AU  - Chandni Hindocha
AU  - Paul Liknaitzky
AU  - Sean M. McGuigan
AU  - Sejal Mehta
AU  - Mimi Pierce
AU  - Dimitris Repantis
AU  - Claire Roberts
AU  - Frank Wiegand
AU  - Robert Conley
PY  - 2026
DA  - 2026/10/26
JO  - JAMA
DO  - 10.1001/jama.2026.18380
UR  - https://doi.org/10.1001/jama.2026.18380
SN  - 0098-7484
SN  - 1538-3598
ER  -